FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549	
------------------------	--

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	ırden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BUTEL JEAN LUC					2. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
——————————————————————————————————————					L	1 3							_	X		r (give title		10% Ov Other (s	· I
(Last) (First) (Middle) C/O RANI THERAPEUTICS LLC						3. Date of Earliest Transaction (Month/Day/Year) 05/25/2022									below)			below)	
2051 RINGWOOD AVE.					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X Form filed by One Reporting Person					
SAN JOS	SE C	A	95131											Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)						Execution Date,			Code (Instr. 5)				4 and Securitie Benefici Owned F		s ally ollowing	Form (D) o	n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Pri	се	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion Date Courity or Exercise (Month/Day/Year) if any				ate, T	I. Fransac Code (I 3)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 an	5	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisab		expiration Date	Title	Amou or Numb of Share	ber					
Stock Option (Right to Buy)	\$10.89	05/25/2022			A		41,416		(1)	0	05/24/2032	Class A Common Stock	41,4	-16	\$0.00	41,416	6	D	

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

Remarks:

/s/ Svai Sanford, Attorney-in-Fact for Jean-Luc Butel

05/27/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.